Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Biotechnology
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. It operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.


NDAQ:LEXX - Post by User

Lexaria Bioscience Corp > ceo purchased $118K worth of shares this week
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(125)
•••
Comment by ranmanon Dec 04, 2024 8:37am
29 Views
Post# 36344735

RE:ceo purchased $118K worth of shares this week

RE:ceo purchased $118K worth of shares this weekOUR CEO BOUGHT ON THE OPEN MARKET SHORTLY AFTER THIS INTERVIEW

https://www.b-tv.com/post/lexaria-bioscience-advancing-glp-1-drug-delivery-with-dehydratech-technology-btv-feature

ranman wrote:
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=318763542&type=HTML&symbol=LEXX&cdn=af33ccd8a32292b10f9e4bb89dccd765&companyName=Lexaria+Bioscience+Corp.&formType=4&formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&dateFiled=2024-12-03



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities